AR and breast cancer: With these goals in mind we selected a panel of prostate and breast cancer cell lines and used automated image analysis routines to quantify endogenous AR nuclear levels and localization in response to DHT (Figure 1A–1C), at the single cell level, using a validated N-terminal AR antibody (AR441).